A new way to screen for
Autism Spectrum Disorder (Autism) …
NeuroQure’s early Autism detection test is the first-of-its-kind autism early detection test uses a skin sample to predicts the risk of autism with a likelihood of over 80%
Get StartedNeuroQure’s early Autism detection test is redefining how autism is diagnosed by allowing parents to know whether their child has the biomarkers of autism within days.
With a single tiny skin sample, the early Autism detection test predicts the risk of autism, enabling parents to expedite a safe infant stimulation treatment plan with a healthcare provider.
The Early Autism Detection Test
RequestHow it Works?
Tissue sample or discarded foreskin
Tissue sent to NeuroQure’s Lab
Cultured tissues analyzed using patented technique
High throughput capacity screening
Results delivered to in days
The early Autism detection test screens, as early as in a newborn, for a functional cellular signal strongly associated with the diagnosis of ASD using research-grade ADOS testing at 2 years age, long considered the gold-standard of ASD testing.
The Autism test is an early detection test that, as detailed in substantial clinical data and several published papers, identifies a way to diagnose autism by monitoring a specific calcium signal in skin cells. Calcium signaling in skin cells reflects that in brain neurons, and of neurotypical individuals have a robust signal that is lost in ASD. For individuals with a low signal there is a high risk they are susceptible to Autism, and will be diagnosed with diagnostic behavioral tests which can only be used after they reach age 2.
Backed by rigorous clinical evidence
The early Autism detection test was discovered and evaluated and achieved recognition with an issued patent in based on clinical studies at UC Irvine’s Center for Autism Research and Translation. The NQ ASD test based on this discovery was developed by NeuroQure in its clinical laboratory that is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) and accredited by the College of American Pathologists (CAP).
Intervene early with Autism screening
NeuroQure’s early Autism detection test redefines when you can detect Autism. Despite the prevalence of Autism affecting 1 in every 36 US children, a scientifically validated method for diagnosis has not been possible until 24 months age, and is notably absent until after the window for many critical early developmental milestones have closed . Adding the early Autism detection test can allow therapeutic intervention before those opportunities are lost, so promises superiority to mere catch-up development as is currently available after age 2. NeuroQure’s proprietary technology in the NQ ASD early Autism detection test relies upon two foundational Nobel Prize-winning neuroscience discoveries, patch clamp electrophysiology and calcium sensitive dyes, and is consistent with the genomic architecture of ASD revealed in gene sequencing strudies of ASD.
False positive and false negative results do occur.
NeuroQure is transforming Autism detection
The early Autism detection test is the first innovation from NeuroQure, a leading healthcare company whose mission is to detect Autism early, when it can be treated.
NeuroQure is committed to innovative Autism screening that can help find Autism early, enabling parents to change the trajectory of their children’s lives through early intervention with approved therapies.